MV BioTherapeutics ApyraVax

MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraVax MV BioTherapeutics ApyraMed ApyraVax MV BioTherapeutics ApyraVax ATP C. difficile MV BioTherapeutics ApyraVax Vaccine-mediated stimulation of gut immune system​ Oral vaccination with ApyraVax​ MV BioTherapeutics ApyraVax MV BioTherapeutics ApyraVax MV BioTherapeutics ApyraVax ApyraVax mechanism Infection by Clostridioides difficile Secretory IgA MV BioTherapeutics ApyraVax MV BioTherapeutics ApyraMed ApyraVax Normal intestinal homeostasis​ Generation of high-affinity secretory IgA​ Back to normal intestinal homeostasis​ MV BioTherapeutics ApyraVax C. difficile clearance by high-affinity secretory IgA​

Technology

The ApyraVax technology exploits the live attenuated typhoid vaccine as vector to deliver orally an enzyme that breaks down ATP (apyrase) together with desired antigen/s.

The innovative feature is the unique ability to generate high-affinity secretory IgA that are protective towards the target infectious agent.

MV BioTherapeutics ApyraVax